Search Results
Search for other papers by Mohammed S Razzaque in
Google Scholar
PubMed
factor‐23 (FGF23), can influence vitamin D metabolism by suppressing 1α(OH)ase activity ( 8 ). Figure 1 Simplified diagram illustrating various functions of vitamin D. Vitamin D is a multifunctional hormone and has been shown to have beneficial
Search for other papers by Magdaléna Fořtová in
Google Scholar
PubMed
Search for other papers by Lenka Hanousková in
Google Scholar
PubMed
Search for other papers by Martin Valkus in
Google Scholar
PubMed
Search for other papers by Jana Čepová in
Google Scholar
PubMed
Search for other papers by Richard Průša in
Google Scholar
PubMed
Search for other papers by Karel Kotaška in
Google Scholar
PubMed
frequently used indicator of successful parathyroidectomy; nevertheless, the information about changes of fibroblast growth factor 23 (FGF23) levels is scarce ( 2 , 3 ). FGF23 is a phosphaturic peptide promoting phosphate excretion in urine. It is a member
Search for other papers by Shu-Meng Hu in
Google Scholar
PubMed
Search for other papers by Yang-Juan Bai in
Google Scholar
PubMed
Search for other papers by Ya-Mei Li in
Google Scholar
PubMed
Search for other papers by Ye Tao in
Google Scholar
PubMed
Search for other papers by Xian-Ding Wang in
Google Scholar
PubMed
Search for other papers by Tao Lin in
Google Scholar
PubMed
Search for other papers by Lan-Lan Wang in
Google Scholar
PubMed
Search for other papers by Yun-Ying Shi in
Google Scholar
PubMed
closely associated with bone fracture, graft loss, cardiovascular events and all-cause death after KT ( 2 , 3 , 4 ). Fibroblast growth factor 23 (FGF23) is a phosphaturic hormone produced by osteocytes and osteoblasts. By binding to FGF receptor 1
Search for other papers by Johanna Öberg in
Google Scholar
PubMed
Search for other papers by Rolf Jorde in
Google Scholar
PubMed
Diagnostic Clinic, University Hospital of North Norway, Tromso, Norway
Search for other papers by Yngve Figenschau in
Google Scholar
PubMed
Search for other papers by Per Medbøe Thorsby in
Google Scholar
PubMed
Search for other papers by Sandra Rinne Dahl in
Google Scholar
PubMed
Search for other papers by Anne Winther in
Google Scholar
PubMed
Division of Internal Medicine, University Hospital of North Norway, Tromso, Norway
Search for other papers by Guri Grimnes in
Google Scholar
PubMed
to 25(OH)D measurements ( 15 , 16 ). The aim of this study was therefore to compare 25(OH)D, 1,25(OH) 2 D, 24,25(OH) 2 D, DBP, free 25(OH)D, 1,25(OH) 2 D)/25(OH)D, VMR, parathyroid hormone (PTH) and fibroblast growth factor 23 (FGF23), according to
Department of Clinical Chemistry, Hematology and Immunology, Noordwest Ziekenhuis, Alkmaar, The Netherlands
Search for other papers by Niek F Dirks in
Google Scholar
PubMed
Search for other papers by Etienne Cavalier in
Google Scholar
PubMed
Amsterdam Gastroenterology, Endocrinology & Metabolism, Amsterdam, The Netherlands
Amsterdam UMC location University of Amsterdam, Department of Clinical Chemistry, Endocrine Laboratory, Amsterdam, The Netherlands
Amsterdam Reproduction & Development Research Institute, Amsterdam, The Netherlands
Search for other papers by Annemieke C Heijboer in
Google Scholar
PubMed
tightly regulated by parathyroid hormone (PTH), fibroblast growth factor 23 (FGF23), calcium, phosphate, and 1,25(OH) 2 D itself. PTH upregulates the expression of 1α-hydroxylation, while FGF23 and 1,25(OH) 2 D downregulate its expression. Apart from renal
Search for other papers by Caroline Nguyen in
Google Scholar
PubMed
Search for other papers by Elisabeth Celestin in
Google Scholar
PubMed
Search for other papers by Delphine Chambolle in
Google Scholar
PubMed
Paris Saclay University, AP-HP, DMU SEA, Endocrinology and Diabetes for Children, Le Kremlin Bicêtre, France
Reference Center for Rare Disorders of the Calcium and Phosphate Metabolism, Le Kremlin Bicêtre, France
Filière OSCAR and Platform of Expertise for Rare Diseases Paris-Saclay, Bicêtre Paris-Saclay Hospital, INSERM-U1185, Le Kremlin Bicêtre, France
Search for other papers by Agnès Linglart in
Google Scholar
PubMed
APHP-Center for Rare Diseases of Calcium and Phosphate Metabolism, Paris, France
Hôpital Bretonneau, Service de Médecine Bucco-Dentaire, GH Nord Université de Paris, Paris, France
Université de Paris, Inserm U1163, Institute Imagine, Paris, France
Search for other papers by Martin Biosse Duplan in
Google Scholar
PubMed
APHP-Center for Rare Diseases of Calcium and Phosphate Metabolism, Paris, France
Hôpital Bretonneau, Service de Médecine Bucco-Dentaire, GH Nord Université de Paris, Paris, France
Université de Paris, URP2496, Paris, France
Search for other papers by Catherine Chaussain in
Google Scholar
PubMed
Université de Paris Laboratoire ECEVE INSERM, UMR1123, Hôpital Robert Debré, Paris, France
Centre de Reference, Maladies Orales et Dentaires Rares, Hôpital Rothschild, APHP, Paris, France
Filière de Santé Maladies Rares TETECOU, Malformations Rares de la tête, du cou et des dents, Hôpital Necker, Paris, France
Search for other papers by Lisa Friedlander in
Google Scholar
PubMed
Member States to develop plans and strategies on this topic. X-linked hypophosphatemia (XLH) is a rare, hereditary, progressive, and lifelong phosphate-wasting disorder characterized by pathological elevations in fibroblast growth factor (FGF) 23
Search for other papers by Nancy Martini in
Google Scholar
PubMed
Search for other papers by Lucas Streckwall in
Google Scholar
PubMed
Search for other papers by Antonio Desmond McCarthy in
Google Scholar
PubMed
) ( 56 ) and alterations in bone and mineral metabolism: it negatively affects bone formation by inducing resistance to PTH and positively correlates with FGF23 levels in patients with chronic kidney disease-related osteodystrophy ( 57 ). Fetuin A
School of Nursing, Institute of Clinical Sciences, University of Birmingham, Edgbaston, Birmingham, UK
Search for other papers by Jane Fletcher in
Google Scholar
PubMed
Search for other papers by Emma L Bishop in
Google Scholar
PubMed
Search for other papers by Stephanie R Harrison in
Google Scholar
PubMed
Search for other papers by Amelia Swift in
Google Scholar
PubMed
Search for other papers by Sheldon C Cooper in
Google Scholar
PubMed
Search for other papers by Sarah K Dimeloe in
Google Scholar
PubMed
Search for other papers by Karim Raza in
Google Scholar
PubMed
Search for other papers by Martin Hewison in
Google Scholar
PubMed
-hydroxylase), with this activity occurring primarily in the proximal tubules of the kidney under positive and negative control by parathyroid hormone (PTH) and fibroblast growth factor 23 (FGF23) respectively. Binding to its cognate nuclear vitamin D receptor (VDR
Search for other papers by Souad Daamouch in
Google Scholar
PubMed
Search for other papers by Sylvia Thiele in
Google Scholar
PubMed
Search for other papers by Lorenz Hofbauer in
Google Scholar
PubMed
Search for other papers by Martina Rauner in
Google Scholar
PubMed
and Metabolism 2010 95 2248 – 2253 . ( https://doi.org/10.1210/jc.2010-0067 ) 17 Mäkitie RE Kämpe A Costantini A Alm JJ Magnusson P & Mäkitie O . Biomarkers in WNT1 and PLS3 osteoporosis: altered concentrations of DKK1 and FGF23
PhyMedExp, Université de Montpellier, INSERM, CNRS, Montpellier, France
Search for other papers by Laurent Maïmoun in
Google Scholar
PubMed
PhyMedExp, Université de Montpellier, INSERM, CNRS, Montpellier, France
Search for other papers by Denis Mariano-Goulart in
Google Scholar
PubMed
Search for other papers by Helena Huguet in
Google Scholar
PubMed
CIC INSERM 1411, Hôpital Gui de Chauliac, CHU Montpellier, Montpellier Cedex 5, France
Institut de Génomique Fonctionnelle, CNRS UMR 5203/INSERM U661/Université Montpellier, Montpellier, France
Search for other papers by Eric Renard in
Google Scholar
PubMed
Search for other papers by Patrick Lefebvre in
Google Scholar
PubMed
CIC INSERM 1411, Hôpital Gui de Chauliac, CHU Montpellier, Montpellier Cedex 5, France
Search for other papers by Marie-Christine Picot in
Google Scholar
PubMed
Search for other papers by Anne-Marie Dupuy in
Google Scholar
PubMed
Département de Biochimie, Hôpital Lapeyronie, CHU Montpellier, Montpellier, France
Search for other papers by Jean-Paul Cristol in
Google Scholar
PubMed
Département d’Urgence et Post-Urgence Psychiatrique, Hôpital Lapeyronie, CHU Montpellier, Montpellier, France
Search for other papers by Philippe Courtet in
Google Scholar
PubMed
Search for other papers by Vincent Boudousq in
Google Scholar
PubMed
Search for other papers by Antoine Avignon in
Google Scholar
PubMed
Département d’Urgence et Post-Urgence Psychiatrique, Hôpital Lapeyronie, CHU Montpellier, Montpellier, France
Search for other papers by Sébastien Guillaume in
Google Scholar
PubMed
Département Endocrinologie, Nutrition, Diabète, Equipe Nutrition, Diabète, CHU Montpellier, Montpellier, France
Search for other papers by Ariane Sultan in
Google Scholar
PubMed
JD Smith S Brychta RJ Wang J Idelson C Perron RM Werner CD Phan GQ Kammula US Irisin and FGF21 are cold-induced endocrine activators of brown fat function in humans . Cell Metabolism 2014 19 302 – 309 . ( https://doi.org/10.1016/j